Trends in Hospitalization for Pediatric Pulmonary Hypertension

Bryan G Maxwell1, Melanie K Nies2, Chinwe C Ajuba-Iwuji3

  • 1Departments of Anesthesiology and Critical Care Medicine, bmaxwell@jhu.edu.

Pediatrics
|July 8, 2015
PubMed

Insights

Pediatric pulmonary hypertension (PH) hospitalizations increased from 1997 to 2012, with rising costs and a shift towards cases without congenital heart disease. Mortality decreased, but PH remains a growing healthcare burden.

Area of Science:

  • Pediatric Cardiology
  • Pulmonary Medicine
  • Health Services Research

Background:

  • Pediatric pulmonary hypertension (PH) is linked to significant illness and death.
  • Existing studies on pediatric PH inpatient care are limited in scope.
  • National data analysis is needed to understand PH hospitalization trends.

Purpose of the Study:

  • To analyze US national data on pediatric PH hospitalizations.
  • To determine trends in volume, demographics, procedures, and resource utilization.
  • To assess the evolving landscape of pediatric PH care.

Main Methods:

  • Retrospective cohort study design.
  • Utilized the Kids' Inpatient Database, a national administrative database.
  • Analyzed pediatric hospital discharge data from 1997 to 2012.

Main Results:

  • Pediatric PH hospitalizations increased from 1997 to 2012 (P < .0001).
  • National hospital charges for PH rose from $926 million to $3.12 billion.
  • PH without congenital heart disease (CHD) became the majority (56.4%), with increasing care in urban teaching hospitals.
  • In-hospital mortality was 5.9% but showed a decreasing trend (P < .0001).

Conclusions:

  • Pediatric PH presents a substantial and increasing healthcare burden.
  • Shifting case mix towards PH without CHD and non-cardiac procedures impacts care.
  • Urban teaching hospitals are increasingly managing pediatric PH, necessitating improved expertise and resource management.
Abstract

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
874
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
766
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
486
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
672
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654